CN112654607B - 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型 - Google Patents

6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型 Download PDF

Info

Publication number
CN112654607B
CN112654607B CN201980058360.8A CN201980058360A CN112654607B CN 112654607 B CN112654607 B CN 112654607B CN 201980058360 A CN201980058360 A CN 201980058360A CN 112654607 B CN112654607 B CN 112654607B
Authority
CN
China
Prior art keywords
xrpd
type
water
present
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980058360.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112654607A (zh
Inventor
陈向阳
王作鹏
俞丽琴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Priority to CN202211635896.1A priority Critical patent/CN116496247A/zh
Publication of CN112654607A publication Critical patent/CN112654607A/zh
Application granted granted Critical
Publication of CN112654607B publication Critical patent/CN112654607B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980058360.8A 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型 Active CN112654607B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211635896.1A CN116496247A (zh) 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732994P 2018-09-18 2018-09-18
US62/732,994 2018-09-18
PCT/CN2019/106433 WO2020057549A1 (en) 2018-09-18 2019-09-18 Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211635896.1A Division CN116496247A (zh) 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型

Publications (2)

Publication Number Publication Date
CN112654607A CN112654607A (zh) 2021-04-13
CN112654607B true CN112654607B (zh) 2023-01-13

Family

ID=69888278

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980058360.8A Active CN112654607B (zh) 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型
CN202211635896.1A Pending CN116496247A (zh) 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211635896.1A Pending CN116496247A (zh) 2018-09-18 2019-09-18 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型

Country Status (11)

Country Link
US (1) US11945792B2 (https=)
EP (1) EP3853217B1 (https=)
JP (1) JP2022501351A (https=)
KR (1) KR20210060501A (https=)
CN (2) CN112654607B (https=)
AU (1) AU2019341284B2 (https=)
CA (1) CA3111114A1 (https=)
ES (1) ES2951420T3 (https=)
MX (1) MX2021003064A (https=)
SG (1) SG11202102116XA (https=)
WO (1) WO2020057549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
CN107257686A (zh) * 2014-12-18 2017-10-17 普林斯匹亚生物制药公司 天疱疮的治疗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
CN107257686A (zh) * 2014-12-18 2017-10-17 普林斯匹亚生物制药公司 天疱疮的治疗
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery

Also Published As

Publication number Publication date
JP2022501351A (ja) 2022-01-06
CN116496247A (zh) 2023-07-28
AU2019341284A1 (en) 2021-04-15
CA3111114A1 (en) 2020-03-26
EP3853217A1 (en) 2021-07-28
WO2020057549A1 (en) 2020-03-26
EP3853217B1 (en) 2023-06-07
US11945792B2 (en) 2024-04-02
CN112654607A (zh) 2021-04-13
AU2019341284B2 (en) 2024-09-05
KR20210060501A (ko) 2021-05-26
SG11202102116XA (en) 2021-04-29
ES2951420T3 (es) 2023-10-20
US20210188801A1 (en) 2021-06-24
MX2021003064A (es) 2021-05-27
EP3853217A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
CN106831716A (zh) 一种alk抑制剂的结晶形式
CN103619852A (zh) 利福昔明的多晶型物及其制备方法
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
CN103360391A (zh) 阿哌沙班新晶型及其制备方法
WO2018006870A1 (zh) Galunisertib的晶型及其制备方法和用途
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
CN108290882A (zh) 用于治疗呼吸道合胞病毒(rsv)感染的n-[(3-氨基-3-氧杂环丁基)甲基]-2-(2,3-二氢-1,1-二氧代-1,4-苯并噻氮*-4(5h)-基)-6-甲基-4-喹唑啉胺的晶形
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2015180682A1 (zh) 一种环肽类化合物的溶剂合物及其制备方法和用途
CN112654607B (zh) 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型
WO2026036924A1 (zh) 一种酪氨酸激酶抑制剂的可药用盐、晶体、制备方法及其用途
CN109897009B (zh) 一种Apabetalone水合物晶型及其制备方法
HK40096475A (zh) 6-(1-丙烯醯基哌啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的晶型
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN103200821A (zh) 非布索坦的多晶型物
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
TW202222818A (zh) 脂化肽的水溶性鹽以及製備與使用其的方法
CN104910147A (zh) 阿哌沙班晶体及其制备方法
HK40048993A (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
CN105985409B (zh) 一种卡非佐米马来酸盐结晶及其制备方法
HK40048993B (en) Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl) nicotinamide
RU2619129C2 (ru) Кристаллические сольваты гидрохлорида 6-(пиперидин-4-илокси)-2н-изохинолин-1-oha
WO2015180681A1 (zh) 一种环肽类化合物的组合物及其制备方法和用途
CN104817557A (zh) 一种盐酸莫西沙星的稳定晶型及其制备方法
CN105399725A (zh) 曲格列汀化合物其盐、晶体、药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048993

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant